Xu J - Search Results

1

Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.

Long L, Xu J, Qi X, Pen Y, Wang C, Jiang W, Peng X, Hu Z, Yi W, Xie L, Lei X, Wang Z, Zhuo L. Long L, et al. Among authors: xu j. Eur J Med Chem. 2024 Jul 5;273:116500. doi: 10.1016/j.ejmech.2024.116500. Epub 2024 May 16. Eur J Med Chem. 2024. PMID: 38776807

2

LncRNA CASC9 activated by STAT3 promotes the invasion of breast cancer and the formation of lymphatic vessels by enhancing H3K27ac-activated SOX4.

Fan SJ, Cui Y, Li YH, Xu JC, Shen YY, Huang H, Hu ZC. Fan SJ, et al. Kaohsiung J Med Sci. 2022 Sep;38(9):848-857. doi: 10.1002/kjm2.12573. Epub 2022 Jul 21. Kaohsiung J Med Sci. 2022. PMID: 35860965 Free article.

3

Prognosis comparison between intraoperative radiotherapy and whole-breast external beam radiotherapy for T1-2 stage breast cancer without lymph node metastasis treated with breast-conserving surgery: A case-control study after propensity score matching.

Chen Q, Qu L, He Y, Xu J, Deng Y, Zhou Q, Yi W. Chen Q, et al. Among authors: xu j. Front Med (Lausanne). 2022 Aug 3;9:919406. doi: 10.3389/fmed.2022.919406. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35991652 Free PMC article.

4

Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.

Zhu J, Chen Q, Zeng L, Gao H, Wu T, He Y, Xu J, Pang J, Peng J, Deng Y, Han Y, Yi W. Zhu J, et al. Among authors: xu j. Front Immunol. 2023 Oct 12;14:1236806. doi: 10.3389/fimmu.2023.1236806. eCollection 2023. Front Immunol. 2023. PMID: 37901236 Free PMC article.

5

Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.

Gao H, Ouyang D, Guan X, Xu J, Chen Q, Zeng L, Pang J, Zou Q, Qian K, Yi W. Gao H, et al. Among authors: xu j. BMC Cancer. 2024 Jan 9;24(1):50. doi: 10.1186/s12885-024-11815-8. BMC Cancer. 2024. PMID: 38195475 Free PMC article.

6

Circulating tumor DNA: from discovery to clinical application in breast cancer.

Xu J, Gao H, Guan X, Meng J, Ding S, Long Q, Yi W. Xu J, et al. Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024. Front Immunol. 2024. PMID: 38745646 Free PMC article. Review.

7

Interleukin signaling in the regulation of natural killer cells biology in breast cancer.

Xu J, Gao H, Azhar MS, Xu H, Chen S, Li M, Ni X, Yan T, Zhou H, Long Q, Yi W. Xu J, et al. Among authors: xu h. Front Immunol. 2024 Sep 24;15:1449441. doi: 10.3389/fimmu.2024.1449441. eCollection 2024. Front Immunol. 2024. PMID: 39380989 Free PMC article. Review.

8

Prognostic and immune correlation of IDO1 promoter methylation in breast cancer.

Ding S, Yang R, Meng J, Guan X, Hong Y, Xu J, Qu L, Ji J, Yi W, Zou Q, Long Q. Ding S, et al. Among authors: xu j. Sci Rep. 2024 Nov 13;14(1):27836. doi: 10.1038/s41598-024-79149-w. Sci Rep. 2024. PMID: 39537860 Free PMC article.

9

CircDNA2-Educated YTHDF2 Phase Separation Promotes PM_2.5-Induced Malignant Transformation Through the Blunting of GADD45A Expression.

Xu J, Ling Z, Yin L, Xu D, Wu S, Chen R. Xu J, et al. Adv Sci (Weinh). 2025 Jan 17:e2410532. doi: 10.1002/advs.202410532. Online ahead of print. Adv Sci (Weinh). 2025. PMID: 39823477

10

Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti-angiogenic Therapy in Armored and Cold Tumors.

Mei J, Yang K, Zhang X, Luo Z, Tian M, Fan H, Chu J, Zhang Y, Ding J, Xu J, Cai Y, Yin Y. Mei J, et al. Among authors: xu j. Adv Sci (Weinh). 2025 Jan 17:e2409147. doi: 10.1002/advs.202409147. Online ahead of print. Adv Sci (Weinh). 2025. PMID: 39823457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,356 results

Search Page

Filters